Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPT003
MIFTS: 63

Hepatitis a

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Mental diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hepatitis a

About this section

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 74 42 44 15 71
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases Immune diseases Nephrological diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:12549
MeSH 44 D006506
NCIt 50 C3096
SNOMED-CT 67 40468003
ICD10 32 B15.0 B15.9
UMLS 71 C0019159
Sources

Summaries for Hepatitis a

About this section
MedlinePlus : 42 What is Hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. What is hepatitis A? Hepatitis A is a type of viral hepatitis. It causes an acute, or short-term, infection. This means that people usually get better without treatment after a few weeks. Thanks to a vaccine, hepatitis A is not very common in the United States. What causes hepatitis A? Hepatitis A is caused by the hepatitis A virus. The virus spreads through contact with an infected person's stool. This can happen if you Eat food made by someone who has the virus and did not properly wash their hands after using the bathroom Drink contaminated water or eat foods that were rinsed with contaminated water Have close personal contact with someone who has hepatitis A. This could be through certain types of sex (like oral-anal sex), taking care of someone who is ill, or using illegal drugs with others. Who is at risk for hepatitis A? Although anyone can get hepatitis A, you are at higher risk if you Travel to developing countries Have sex with someone who has hepatitis A Are a man who has sex with men Use illegal drugs Are experiencing homelessness Live with or care for someone who has hepatitis A Live with or care for a child recently adopted from a country where hepatitis A is common What are the symptoms of hepatitis A? Not everyone with hepatitis A has symptoms. Adults are more likely to have symptoms than children. If you do have symptoms, they usually start 2 to 7 weeks after infection. They can include Dark yellow urine Diarrhea Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Abdominal pain Yellowish eyes and skin, called jaundice The symptoms usually last less than 2 months, although some people can be ill for as long as 6 months. You are at a higher risk of getting a more severe infection from hepatitis A if you also have HIV, hepatitis B, or hepatitis C. What other problems can hepatitis A cause? In rare cases, hepatitis A may lead to liver failure. This is more common in adults over age 50 and in people who have another liver. How is hepatitis A diagnosed? To diagnose hepatitis A, your health care provider may use many tools: A medical history, which includes asking about your symptoms A physical exam Blood tests, including tests for viral hepatitis What are the treatments for hepatitis A? There is no specific treatment for hepatitis A. The best way to recover is to rest, drink plenty of liquids, and eat healthy foods. Your provider may also suggest medicines to help relieve symptoms. In more severe cases, you may need care in a hospital. Can hepatitis A be prevented? The best way to prevent hepatitis A is to get the hepatitis A vaccine. It is also important to have good hygiene, especially washing your hands thoroughly after you go to the bathroom. National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to acute liver failure and hepatitis e, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Neomycin and Raltitrexed have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and bone, and related phenotypes are cardiovascular system and immune system

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 74 Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral... more...

Sources

Related Diseases for Hepatitis a

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 998)
# Related Disease Score Top Affiliating Genes
1 acute liver failure 32.2 GPT F2 ALB
2 hepatitis e 31.7 TNF IFNG GPT F2 ALB
3 acute kidney failure 31.2 HAVCR1 GPT F2 ALB
4 hepatitis d 31.2 IFNA1 GPT F2
5 cholestasis 31.1 SERPINA1 GPT F2 ALB
6 cholecystitis 31.1 GPT F2 ALB
7 hepatitis 31.0 TNF TICAM1 SEPSECS MAVS IKBKG IFNG
8 hepatic encephalopathy 31.0 TNF GPT F2 ALB
9 syphilis 31.0 GPT CD4 ALB
10 acalculous cholecystitis 31.0 GPT F2 ALB
11 hepatorenal syndrome 30.9 GPT F2 ALB
12 acute pancreatitis 30.8 TNF IL1B IL10 GPT
13 viral hepatitis 30.8 TNF SERPINA1 SEPSECS IL1B IL10 IFNG
14 hepatic coma 30.8 GPT F3 F2 ALB AFP
15 drug-induced hepatitis 30.7 TNF GPT ALB
16 liver disease 30.7 TNF SERPINA1 SEPSECS IL1B IFNA1 GPT
17 autoimmune hepatitis 30.7 TNF SEPSECS IL10 IFNA1 GPT F2
18 pancreatitis 30.7 TNF SERPINA1 IL1B IL10
19 bilirubin metabolic disorder 30.7 GPT F3 F2 ALB
20 alcoholic hepatitis 30.6 TNF IL1B IL10 IFNG GPT F2
21 encephalitis 30.6 TNF TICAM1 IL1B IL10
22 typhoid fever 30.5 TNF IL1B IFNG GPT F2 ALB
23 measles 30.5 TNF IL1B IFNG IFNA1
24 hepatitis c virus 30.5 TICAM1 MAVS IFNG HAVCR2 GPT
25 hepatitis b 30.5 TNF IFNG IFNA1 GPT F2 CTLA4
26 rubella 30.5 TNF IL1B IL10 IFNG
27 anemia, autoimmune hemolytic 30.4 GYPA CTLA4 CD4
28 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 IL10 IFNG CTLA4
29 poliomyelitis 30.4 TNF IL10 IFNG IFNA1 CD4
30 granulomatous hepatitis 30.4 TNF GPT CTLA4 CD4 ALB
31 acute kidney tubular necrosis 30.4 TNF HAVCR1 GPT F2 CD4 ALB
32 diphtheria 30.4 TNF IL1B IFNG ALB
33 pertussis 30.4 TNF TICAM1 IL1B IL10
34 meningoencephalitis 30.3 TNF IL10 CD4 ALB
35 arachnoiditis 30.3 TNF IL1B CD4
36 gastroenteritis 30.3 TNF IL1B IL10 IFNG IFNA1 ALB
37 tetanus 30.3 TNF IL1B IL10 IFNG ALB
38 mumps 30.3 TNF IL1B IL10 IFNG IFNA1
39 hepatitis c 30.2 TNF MAVS IL10 IFNG IFNA1 GPT
40 sclerosing cholangitis 30.2 TNF IL10 GPT F2 CTLA4 ALB
41 dengue disease 30.2 TNF IL10 IFNG IFNA1
42 hemopericardium 30.2 F3 F2
43 eclampsia 30.2 TNF F2 ALB
44 biliary atresia 30.2 IFNG GPT F2 ALB
45 purpura 30.2 TNF IL1B IL10 IFNG F3 F2
46 primary biliary cholangitis 30.2 SEPSECS GPT F2 CTLA4 CD4 ALB
47 non-alcoholic fatty liver disease 30.2 TNF SERPINA1 IL1B IL10 GPT ALB
48 acute myocarditis 30.1 TNF IL10 CD4
49 optic neuritis 30.1 TNF IL1B IL10
50 optic nerve disease 30.1 TNF IL1B CD4 ALB

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a
Sources

Symptoms & Phenotypes for Hepatitis a

About this section

Symptoms:

12
  • • vomiting
  • • fatigue
  • • fever
  • • jaundice
  • • abdominal pain
  • • nausea
  • • loss of appetite
  • • joint pain
  • • clay-colored bowel movements

UMLS symptoms related to Hepatitis a:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, dyspepsia, icterus, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.23 ALB CTLA4 F2 F3 HAVCR2 IFNG
2 immune system MP:0005387 10.22 ALB CD4 CTLA4 F2 F3 HAVCR2
3 mortality/aging MP:0010768 10.16 AFP ALB CD4 CTLA4 F2 F3
4 digestive/alimentary MP:0005381 10.13 ALB CD4 CTLA4 F2 IFNG IKBKG
5 integument MP:0010771 10.07 CD4 CTLA4 F2 F3 IFNG IKBKG
6 liver/biliary system MP:0005370 9.92 AFP ALB CTLA4 IFNG IKBKG IL10
7 neoplasm MP:0002006 9.81 AFP ALB F3 IFNG IKBKG IL10
8 normal MP:0002873 9.61 ALB CD4 CTLA4 F2 F3 IFNG
9 respiratory system MP:0005388 9.23 CTLA4 F2 F3 IFNG IL10 MAVS
Sources

Drugs & Therapeutics for Hepatitis a

About this section

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 931)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
2
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
3
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
4
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
7
Lenograstim Approved, Investigational Phase 4 135968-09-1
8
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
9
parecoxib Approved Phase 4 198470-84-7
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Fosamprenavir Approved Phase 4 226700-79-4 131536
12
Metformin Approved Phase 4 657-24-9 14219 4091
13
Racepinephrine Approved Phase 4 329-65-7 838
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15
Desflurane Approved Phase 4 57041-67-5 42113
16
Zidovudine Approved Phase 4 30516-87-1 35370
17
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
18
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Simethicone Approved Phase 4 8050-81-5
21
Atorvastatin Approved Phase 4 134523-00-5 60823
22
Citalopram Approved Phase 4 59729-33-8 2771
23
Didanosine Approved Phase 4 69655-05-6 50599
24
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
25
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
26
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
27
Losartan Approved Phase 4 114798-26-4 3961
28
Nelfinavir Approved Phase 4 159989-64-7 64143
29
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
30
Cobicistat Approved Phase 4 1004316-88-4
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
33
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
34
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
35
Pentetic acid Approved Phase 4 67-43-6
36
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
37
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
38
Ziprasidone Approved Phase 4 146939-27-7 60854
39
Tigecycline Approved Phase 4 220620-09-7 5282044
40
Meperidine Approved Phase 4 57-42-1 4058
41
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
42
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
43
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
44
Polyestradiol phosphate Approved Phase 4 28014-46-2
45
Insulin aspart Approved Phase 4 116094-23-6 16132418
46
Deferiprone Approved Phase 4 30652-11-0 2972
47
Baclofen Approved Phase 4 1134-47-0 2284
48
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
49
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
50
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548

Interventional clinical trials:

(show top 50) (show all 5495)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
3 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
4 Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines Unknown status NCT03231605 Phase 4
5 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
6 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
7 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Unknown status NCT02764671 Phase 4
8 Evaluate the Efficacy and Safety of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Who Pretreated With Tenofovir Disoproxil Fumarate Unknown status NCT03485534 Phase 4 Tenofovir Disoproxil Fumarate;Tenofovir Disoproxil
9 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
10 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
11 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
12 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
13 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
14 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
15 The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X) Unknown status NCT03801538 Phase 4 Peginterferon Alfa;Nucleoside Analog (Substance)
16 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
17 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
18 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
19 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
20 Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time Unknown status NCT01926860 Phase 4
21 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
22 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
23 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
24 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
25 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
26 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
27 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
28 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
29 Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood Unknown status NCT01341275 Phase 4
30 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
31 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
32 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
33 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
34 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
35 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
36 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
37 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
38 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
39 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
40 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
41 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
42 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
43 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02745704 Phase 4 Peginterferon alfa
44 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4
45 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
46 A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20) Unknown status NCT00216229 Phase 4
47 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
48 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
49 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
50 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Sources

Genetic Tests for Hepatitis a

About this section
Sources

Anatomical Context for Hepatitis a

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

19
Liver

MalaCards organs/tissues related to Hepatitis a:

40
Liver, Bone Marrow, Bone, T Cells, Kidney, Colon, Endothelial
Sources

Publications for Hepatitis a

About this section

Articles related to Hepatitis a:

(show top 50) (show all 12397)
# Title Authors PMID Year
1
Foodborne transmission of hepatitis A and hepatitis E viruses: A literature review. 61 42
33257099 2021
2
Twitter Communication During an Outbreak of Hepatitis A in San Diego, 2016-2018. 42 61
33001731 2020
3
Genetic diversity, haplotype analysis, and risk factor assessment of hepatitis A virus isolates from the West Bank, Palestine during the period between 2014 and 2016. 61 42
33306686 2020
4
Enterically transmitted hepatitis in the third millennium in northeastern Romania. 61
33603881 2021
5
Hepatitis A virus-induced hsa-miR-146a-5p attenuates IFN-β signaling by targeting adaptor protein TRAF6. 61
33459883 2021
6
Effect of Plant-Derived Proteases on Infectivity of Tulane Virus, Murine Norovirus, and Hepatitis A Virus. 61
33125048 2021
7
Hepatitis A. 61
33554785 2021
8
Survival and Inactivation by Advanced Oxidative Process of Foodborne Viruses in Model Low-Moisture Foods. 61
33501613 2021
9
Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. 61
33609034 2021
10
Acquired ichthyosis and false-positive hepatitis A serology as paraneoplastic phenomena in anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. 61
33597164 2021
11
[Expert consensus on informed consent for vaccination (part one)]. 61
33548950 2021
12
[Expert consensus on informed consent for vaccination(Part One)]. 61
33548951 2021
13
Hepatitis A Person-to-Person Outbreaks: Epidemiology, Morbidity Burden, and Factors Associated With Hospitalization-Multiple States, 2016-2019. 61
33097935 2021
14
Endemicity change of hepatitis A infection necessitates vaccination in food handlers: An Indian perspective. 61
33595412 2021
15
Hepatitis A outbreak among MSM in Berlin due to low vaccination coverage: Epidemiology, management, and successful interventions. 61
33207272 2021
16
Recent outbreaks of severe hepatitis A virus infections in Vienna. 61
32940811 2021
17
Relationship between cases of hepatitis A and flood areas, municipality of Encantado, Rio Grande do Sul, Brazil. 61
33605346 2021
18
Complication of Hepatitis A Infection: Case Report of Acute Inflammatory Demyelinating Polyneuropathy. 61
33560967 2021
19
Nosocomial hepatitis A outbreak among healthcare workers and patients in a community hospital during an ongoing statewide outbreak. 61
32880246 2021
20
Lessons from intensified surveillance of viral hepatitis A, Israel, 2017 and 2018. 61
33573709 2021
21
Public Health Responses to Person-to-Person Hepatitis A Outbreaks. 61
33097940 2021
22
[Viral hepatitis A-E]. 61
33443614 2021
23
Missed opportunities for sexual transmitted infections testing for HIV pre-exposure prophylaxis users: a systematic review. 61
33605081 2021
24
A new assay for quantitative detection of hepatitis A virus. 61
33152410 2021
25
Assessment of Enteric Viruses During a Hepatitis Outbreak in Detroit MI using Wastewater Surveillance and Metagenomic Analysis. 61
33550682 2021
26
Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study. 61
33038136 2021
27
Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. 61
33159831 2021
28
Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data. 61
33574154 2021
29
Enteric viruses in lentic and lotic freshwater habitats from Brazil's Midwest and South regions in the Guarani Aquifer area. 61
33609241 2021
30
Impact of Obesity and Being Overweight on the Immunogenicity to Live Attenuated Hepatitis A Vaccine in Children and Young Adults. 61
33562009 2021
31
Psoriatic arthritis associated with peliosis hepatis: characteristics and therapeutic management. 61
33598810 2021
32
Vaccine-preventable diseases other than tuberculosis, and homelessness: A scoping review of the published literature, 1980 to 2020. 61
33509694 2021
33
Viral hepatitis and pregnancy. 61
33046891 2021
34
Electron Beam Susceptibility of Enteric Viruses and Surrogate Organisms on Fruit, Seed and Spice Matrices. 61
33566336 2021
35
Investigation of F-RNA Bacteriophage as a Tool in Re-Opening Australian Oyster Growing Areas Following Sewage Spills. 61
33548027 2021
36
Identifying Missed Opportunities for Routine Vaccination among People Who Use Drugs. 61
33557231 2021
37
Isolation and complete genome analysis of a novel duck picornavirus in China. 61
33341468 2021
38
Network pharmacology assessment of Qingkailing injection treatment of cholestatic hepatitis. 61
33522210 2021
39
Characterization of low-cost glycolipoprotein biosurfactant produced by Lactobacillus plantarum 60 FHE isolated from cheese samples using food wastes through response surface methodology and its potential as antimicrobial, antiviral, and anticancer activities. 61
33358950 2021
40
Systemic pharmacology understanding of the key mechanism of Sedum sarmentosum Bunge in treating hepatitis. 61
32734365 2021
41
Immunogenicity of Viral Vaccines in the Italian Military. 61
33477366 2021
42
Epidemiological and Clinical History of Viral Hepatitis in Korea. 61
33538133 2021
43
Anaphylaxis to simultaneous administration of inactivated tissue culture hepatitis A vaccine and purified chick embryo cell rabies vaccine after multiple doses. 61
33504524 2021
44
Vaccination coverage rates of military personnel worldwide: a systematic review of the literature. 61
32561973 2021
45
Nationwide seroprevalence of hepatitis A in South Korea from 2009 to 2019. 61
33556072 2021
46
Liver Transplantation Reverses Hepatic Myelopathy in 2 Children With Hepatitis A Infection. 61
33490305 2021
47
Differentiating Biliary Atresia From Idiopathic Neonatal Hepatitis: A Novel Keratin 7 Based Mathematical Approach on Liver Biopsies. 61
33439108 2021
48
Male-Dominant Hepatitis A Outbreak Observed among Non-HIV-Infected Persons in the Northern Part of Tokyo, Japan. 61
33573054 2021
49
Orthotopic liver transplantation for patients with end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: a concise review. 61
33433074 2021
50
Establishment of duplex SYBR Green I-based real-time PCR assay for simultaneous detection of duck hepatitis a virus-1 and duck astrovirus-3. 61
33496724 2021
Sources

Variations for Hepatitis a

About this section
Sources

Expression for Hepatitis a

About this section
Search GEO for disease gene expression data for Hepatitis a.
Sources

Pathways for Hepatitis a

About this section

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.05 TNF TICAM1 SERPINA1 MAVS IL1B IL10
2
TGF-Beta Pathway 63
Show member pathways
 13.56 TNF IL1B IL10 IKBKG IFNG IFNA1
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.37 TNF IL1B IL10 IKBKG IFNG IFNA1
4
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.01 TNF TICAM1 MAVS IL1B IL10 IKBKG
5
Human cytomegalovirus infection 36
Show member pathways
 12.96 TNF TICAM1 IL1B IKBKG IFNA1 CD4
6
Allograft rejection 36 1
Show member pathways
 12.83 TNF IL1B IL10 IFNG IFNA1 CTLA4
7
Measles 36
Show member pathways
 12.81 TNF TICAM1 MAVS IL1B IKBKG IFNG
8
Herpes simplex virus 1 infection 36
12.78 TNF TICAM1 MAVS IL1B IKBKG IFNG
9
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.72 TNF TICAM1 IL1B IKBKG IFNA1 F3
10
4-1BB Pathway 63
Show member pathways
 12.69 TNF IL1B IKBKG IFNG CD4
11
Immune response NFAT in immune response 23
Show member pathways
 12.67 TNF IL10 IKBKG IFNG CD4
12
Th17 cell differentiation 36
Show member pathways
 12.59 TNF IL1B IL10 IKBKG IFNG CD4
13
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.58 TICAM1 MAVS IL1B IKBKG IFNA1
14
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.57 TNF MAVS IKBKG IFNG IFNA1
15
Immune response IL-23 signaling pathway 23
Show member pathways
 12.55 TNF IL1B IL10 IKBKG IFNG F2
16
IL-17 Family Signaling Pathways 64
Show member pathways
 12.36 TNF IL1B IKBKG IFNG
17
Toll Comparative Pathway 63
Show member pathways
 12.34 TNF TICAM1 IL1B IKBKG IFNG
18
Folate Metabolism 1
Show member pathways
 12.34 TNF IL1B IFNG F2 ALB
19
T cell receptor signaling pathway 36
Show member pathways
 12.3 TNF TICAM1 IL1B IL10 IKBKG IFNG
20
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.29 TNF IL1B IL10 IFNG IFNA1
21
Toxoplasmosis 36
Show member pathways
 12.27 TNF IL1B IL10 IKBKG IFNG
22
C-type lectin receptor signaling pathway 36
Show member pathways
 12.25 TNF IL1B IL10 IKBKG
23
Tuberculosis 36
12.24 TNF IL1B IL10 IFNG IFNA1
24
Bacterial infections in CF airways 23
Show member pathways
 12.22 TNF IL1B IKBKG IFNG
25
Necroptosis 36
Show member pathways
 12.2 TNF TICAM1 IL1B IFNG IFNA1
26
NOD-like receptor signaling pathway 36
12.17 TNF TICAM1 MAVS IL1B IKBKG IFNA1
27
Fluid shear stress and atherosclerosis 36
12.12 TNF IL1B IKBKG IFNG
28
Osteoclast differentiation 36
12.07 TNF IL1B IKBKG IFNG
29
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.97 TNF IL10 IFNG GYPA CD4
30
NF-kappa B signaling pathway 36
11.96 TNF TICAM1 IL1B IKBKG
31
Amoebiasis 36
11.94 TNF IL1B IL10 IFNG
32
Yersinia infection 36
11.94 TNF TICAM1 IL1B IL10 IKBKG CD4
33
Hematopoietic cell lineage 36
11.92 TNF IL1B GYPA CD4
34
Rheumatoid arthritis 36
11.89 TNF IL1B IFNG CTLA4
35
NF-kappaB Signaling 4
11.88 TNF TICAM1 MAVS IL1B IL10 IKBKG
36
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.78 TNF IFNG CTLA4
37
Pertussis 36
11.78 TNF TICAM1 IL1B IL10
38
Innate Lymphoid Cell Differentiation Pathways 64
11.76 TNF IL1B IL10 IFNG CD4
39
IgA-Producing B Cells in the Intestine 64
11.71 TNF IL10 CTLA4
40
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.69 TNF IL1B IFNG
41
Lung fibrosis 1
11.69 TNF SERPINA1 IL1B
42
Th1 Differentiation Pathway 64
Show member pathways
 11.68 TNF IL1B IL10 IFNG CD4
43
Dendritic Cells Developmental Lineage Pathway 64
11.64 TNF IL1B IL10 IFNG CD4
44
Cellular Transformation by HTLV1 63
Show member pathways
 11.59 TNF IKBKG IFNG
45
Interleukin-10 signaling 65
11.57 TNF IL1B IL10
46
MSP-RON Signaling 63
11.56 TNF IL1B IFNG
47
Aryl Hydrocarbon Receptor Pathway 1
11.56 TNF IL1B IFNG
48
Th2 Differentiation Pathway 64
11.53 IL10 IFNG CD4
49
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.52 TNF IL1B IFNG
50
FOXA2 and FOXA3 transcription factor networks 1
11.5 F2 ALB AFP
Sources

GO Terms for Hepatitis a

About this section

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TNF SERPINA1 IL1B IL10 IFNG IFNA1
2 extracellular space GO:0005615 9.36 TNF SERPINA1 IL1B IL10 IFNG IFNA1
3 endoplasmic reticulum lumen GO:0005788 9.35 SERPINA1 F2 CD4 ALB AFP

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.1 TNF TICAM1 IL1B IFNG F3
2 adaptive immune response GO:0002250 10.09 IFNG IFNA1 HAVCR2 CTLA4 CD4
3 viral process GO:0016032 10.09 TICAM1 MAVS IKBKG HAVCR1 GYPA CD4
4 inflammatory response GO:0006954 10.06 TNF TICAM1 IL1B IKBKG HAVCR2
5 cellular protein metabolic process GO:0044267 9.99 SERPINA1 F2 ALB AFP
6 defense response to virus GO:0051607 9.98 TICAM1 MAVS IFNG IFNA1
7 blood coagulation GO:0007596 9.97 SERPINA1 IFNA1 F3 F2
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF TICAM1 IL1B IKBKG
9 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.91 TNF TICAM1 MAVS IKBKG CD4
10 immune response GO:0006955 9.91 TNF IL1B IL10 IKBKG IFNG CTLA4
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 TNF MAVS IL1B IL10
12 cellular response to lipopolysaccharide GO:0071222 9.88 TNF TICAM1 IL1B IL10 HAVCR2
13 cytokine-mediated signaling pathway GO:0019221 9.88 TNF IL1B IL10 IFNA1 F3 CD4
14 regulation of insulin secretion GO:0050796 9.87 TNF IL1B IFNG
15 negative regulation of interleukin-6 production GO:0032715 9.87 TNF IL10 HAVCR2
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF IL1B HAVCR2
17 positive regulation of interferon-gamma production GO:0032729 9.85 TNF IL1B HAVCR2
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.85 TNF TICAM1 IKBKG
19 positive regulation of T cell proliferation GO:0042102 9.85 IL1B HAVCR2 CD4
20 positive regulation of tumor necrosis factor production GO:0032760 9.85 TICAM1 MAVS IFNG HAVCR2
21 humoral immune response GO:0006959 9.84 TNF IFNG IFNA1
22 hemostasis GO:0007599 9.82 SERPINA1 F3 F2
23 positive regulation of phagocytosis GO:0050766 9.8 TNF IL1B IFNG
24 negative regulation of T cell proliferation GO:0042130 9.8 IL10 HAVCR2 CTLA4
25 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL10 F2
26 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 TNF TICAM1 IL1B
27 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.76 TNF IL1B IKBKG
28 positive regulation of interleukin-8 production GO:0032757 9.76 TNF MAVS IL1B F3
29 positive regulation of cytokine production GO:0001819 9.73 TNF IL10 IFNG HAVCR2
30 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
31 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 IL10 IFNG
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 TNF IL1B IFNG
33 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 TNF IL1B IL10
35 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
36 vascular endothelial growth factor production GO:0010573 9.67 TNF IL1B
37 macrophage activation involved in immune response GO:0002281 9.67 TICAM1 IFNG HAVCR2
38 negative regulation of interferon-alpha production GO:0032687 9.65 IL10 HAVCR2
39 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.65 TICAM1 MAVS
40 negative regulation of cytokine production involved in immune response GO:0002719 9.65 TNF IL10
41 positive regulation of fever generation GO:0031622 9.64 TNF IL1B
42 positive regulation of protein phosphorylation GO:0001934 9.63 TNF MAVS IL1B IFNG F2 CD4
43 sequestering of triglyceride GO:0030730 9.62 TNF IL1B
44 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 TNF TICAM1 IL1B IFNG
45 negative regulation of myeloid dendritic cell activation GO:0030886 9.61 IL10 HAVCR2
46 positive regulation of vitamin D biosynthetic process GO:0060557 9.57 TNF IFNG
47 positive regulation of nitrogen compound metabolic process GO:0051173 9.56 TNF IFNG
48 positive regulation of chemokine production GO:0032722 9.56 TNF TICAM1 IFNG HAVCR2
49 positive regulation of interleukin-6 production GO:0032755 9.35 TNF TICAM1 MAVS IL1B IFNG
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 8.8 TNF IL1B IFNG

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.13 HAVCR1 GYPA CD4
2 cytokine activity GO:0005125 9.02 TNF IL1B IL10 IFNG IFNA1
Sources

Sources for Hepatitis a

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44